Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Online Reports

 

Volume 28—2022

Volume 28, Number 11—November 2022

Cover of issue Volume 28, Number 11—November 2022

Increased Detection of Carbapenemase-Producing Enterobacterales Bacteria in Latin America and the Caribbean during the COVID-19 Pandemic [PDF - 537 KB - 8 pages]
G. Thomas et al.

During 2020–2021, countries in Latin America and the Caribbean reported clinical emergence of carbapenemase-producing Enterobacterales that had not been previously characterized locally, increased prevalence of carbapenemases that had previously been detected, and co-production of multiple carbapenemases in some isolates. These increases were likely fueled by changes related to the COVID-19 pandemic, including empirical antibiotic use for potential COVID-19–related bacterial infections and healthcare limitations resulting from the rapid rise in COVID-19 cases. Strengthening antimicrobial resistance surveillance, epidemiologic research, and infection prevention and control programs and antimicrobial stewardship in clinical settings can help prevent emergence and transmission of carbapenemase-producing Enterobacterales.

EID Thomas G, Corso A, Pasterán F, Shal J, Sosa A, Pillonetto M, et al. Increased Detection of Carbapenemase-Producing Enterobacterales Bacteria in Latin America and the Caribbean during the COVID-19 Pandemic. Emerg Infect Dis. 2022;28(11):1-8. https://doi.org/10.3201/eid2811.220415
AMA Thomas G, Corso A, Pasterán F, et al. Increased Detection of Carbapenemase-Producing Enterobacterales Bacteria in Latin America and the Caribbean during the COVID-19 Pandemic. Emerging Infectious Diseases. 2022;28(11):1-8. doi:10.3201/eid2811.220415.
APA Thomas, G., Corso, A., Pasterán, F., Shal, J., Sosa, A., Pillonetto, M....Melano, R. (2022). Increased Detection of Carbapenemase-Producing Enterobacterales Bacteria in Latin America and the Caribbean during the COVID-19 Pandemic. Emerging Infectious Diseases, 28(11), 1-8. https://doi.org/10.3201/eid2811.220415.

Volume 28, Number 8—August 2022

Cover of issue Volume 28, Number 8—August 2022

Medscape CME Activity
Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches [PDF - 673 KB - 11 pages]
L. E. Manhart et al.

Since Mycoplasma genitalium was identified 40 years ago, much of the epidemiology has been described, diagnostic tests have been developed and approved, and recommended treatment approaches have been identified. However, the natural history remains incompletely understood, and antimicrobial resistance has rapidly increased. This review summarizes evidence published since the US Centers for Disease Control and Prevention 2015 Sexually Transmitted Diseases Treatment Guidelines. Data on sequelae remain insufficient, macrolide resistance is common, and fluoroquinolone resistance is increasing. Potential benefits of testing and treatment include resolving symptoms, interrupting transmission, and preventing sequelae. Potential harms include cost, patient anxiety, and increasing antimicrobial resistance.

EID Manhart LE, Geisler WM, Bradshaw CS, Jensen JS, Martin DH. Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches. Emerg Infect Dis. 2022;28(8):1-11. https://doi.org/10.3201/eid2808.220094
AMA Manhart LE, Geisler WM, Bradshaw CS, et al. Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches. Emerging Infectious Diseases. 2022;28(8):1-11. doi:10.3201/eid2808.220094.
APA Manhart, L. E., Geisler, W. M., Bradshaw, C. S., Jensen, J. S., & Martin, D. H. (2022). Weighing Potential Benefits and Harms of Mycoplasma genitalium Testing and Treatment Approaches. Emerging Infectious Diseases, 28(8), 1-11. https://doi.org/10.3201/eid2808.220094.

 

Page created: June 09, 2022
Page updated: October 24, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
edit_01 ScholarOne Submission Portal
Issue Select
GO
GO

Spotlight Topics

 

Get Email Updates

To receive email updates about this page, enter your email address:

file_external